Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria Posted on March 17, 2020 at 3:39 pm.Written by Spero Therapeutics ACS Infect. Dis. https://doi.org/10.1021/acsinfecdis.0c00025 Suzanne S. Stokes, Rajender Vemula, Michael J. Pucci View Presentation Post navigation The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study